LAKE ZURICH, Illinois, July 14 --

Fenwal Inc., a global medical technology company focused on improving blood
collection, separation, safety and availability, announced today it has signed a
five-year exclusive worldwide agreement with Verax Biomedical Incorporated to
market, sell and distribute Verax’s unique PanGenera(R) Detection (PGD)
technology, a rapid diagnostic test used to detect bacterial contaminants in
donated blood platelets.

The Verax PGD(R) test is the only rapid test for the detection of bacteria
cleared by the United States Food and Drug Administration (FDA) and CE Marked in
Europe. Development is underway to apply the Verax PGD(R) technology to detect
bacteria in other blood components, tissues for transplantation and cell-based

The Verax PGD(R) test, based on proprietary technology developed by Verax,
consists of an easy-to-use disposable handheld device and reagents that work
together to detect the presence of bacterial contaminants in platelets. The test
can be performed in fewer than 30 minutes and is designed for use in hospitals,
cancer centers and other sites of care as a safeguard immediately prior to

More than 5 million platelet doses are transfused annually worldwide. Platelets
are tiny cells in blood that help blood clot. They are transfused when platelets
levels are low - as, for example, a result of illness or the side effect of some
chemotherapy treatments.

An estimated one in 2,000 to 3,000 platelet units may contain bacteria, and up
to 50 percent of bacteria-contaminated platelets may escape detection by
conventional culture testing, according to experts.(i) Bacteria can cause fatal
reactions, especially in immune-compromised patients. The Verax PGD(R) test, a
rapid immunoassay, targets antigens found on the surface of a wide spectrum of
common bacteria known to be pathogenic to humans in high concentrations.

Bacterial contamination in platelets is a serious concern in transfusion
medicine, said Darrell J. Triulzi, M.D., medical director of the Institute for
Transfusion Medicine and the University of Pittsburgh Medical Center’s
Division of Transfusion Medicine, which is using the Verax PGD(R) test. The
blood center community has made progress with the implementation of
culture-based tests, but these occur at the point of collection when bacteria
levels can be too low for detection. A rapid, point-of-care assay, such as the
Verax PGD(R) test, takes place just prior to transfusion, which is the best time
to detect bacteria levels in platelets and provides a more comprehensive
strategy for patient safety.

Transfusion safety is central to the mission of Fenwal and our customers, said
Ron K. Labrum, Fenwal president and chief executive officer. This agreement is
another example of how Fenwal is bringing advanced technology, ideas and
performance to our vital industry.

Fenwal is a pioneer in the development of products that improve blood safety
worldwide, said Jim Lousararian, Verax president and chief executive officer. We
are confident that with Fenwal’s support we can increase adoption of the
Verax PGD(R) test and improve health-care outcomes by reducing
transfusion-related issues associated with bacterial contamination.

About Verax Biomedical

Verax Biomedical Inc. is a leading developer of rapid tests for detecting
bacterial contaminants in blood cells and tissue. The privately held company was
founded in 1999. Its headquarters and laboratory facilities are in Worcester,
Massachusetts. The Verax PGD(R) test is currently cleared by the FDA as a rapid,
qualitative immunoassay for the detection of bacteria in leukocyte-reduced
apheresis platelets as an adjunct quality-control test following previous
bacterial testing. For more information, visit

About Fenwal

Fenwal Inc. is a global medical technology company focused on improving blood
collection, separation, safety and availability for patient care. Fenwal became
an independent company in 2007, but its roots go back to 1949 with the founding
of Fenwal Laboratories. Fenwal developed the first flexible, disposable
container for blood collection, eliminating complications associated with glass
containers and allowing blood to be separated into therapeutic components.
Today, the company’s products and advanced collection and separation
technologies are used throughout the world to help ensure a safe and available
supply of lifesaving blood and blood products. Fenwal Inc. is based in Lake
Zurich, Illinois. For more information, please visit

(i.) Benjamin R. and Wagner S. The residual risk of sepsis: modeling the effect
of concentration on bacterial detection in 2-bottle culture systems and
estimation of false-negative culture rates. Transfusion 2007; 47:1381-1389.

SOURCE: Fenwal Inc.

Geoffrey Fenton of Fenwal Inc., +1-847-550-2321,